1-20 of 44
Brenda W Cooper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper
Journal: Blood
Blood (2024) 144 (Supplement 1): 2873.
https://doi.org/10.1182/blood-2024-205641
Published: 2024
Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Daniel J. DeAngelo, Andre C. Schuh, Brian A. Jonas, Pamela S. Becker, Anjali S. Advani, Geoffrey L. Uy, Janusz Krawczyk, Harry P. Erba, Gabriel N Mannis, Chun Yew Fong, Florian Kuchenbauer, Mary-Elizabeth M. Percival, Jane L. Liesveld, William Blum, Brenda W Cooper, Alice Mims, Francesco Lanza, Jeroen J.W.M. Janssen, Juan Miguel Bergua Burgues, Tibor Kovacsovics, Norbert Vey, Martina V. Hemmer, Gaetano Bonifacio, Edwin Rock, Pau Montesinos
Journal: Blood
Blood (2024) 144 (Supplement 1): 733.
https://doi.org/10.1182/blood-2024-209097
Published: 2024
Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny
Journal: Blood
Blood (2024) 144 (Supplement 1): 2131.
https://doi.org/10.1182/blood-2024-210550
Published: 2024
Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3087.
https://doi.org/10.1182/blood-2023-173943
Published: 2023
Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne
Journal: Blood
Blood (2023) 142 (Supplement 1): 4862.
https://doi.org/10.1182/blood-2023-180990
Published: 2023
Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson
Journal: Blood
Blood (2023) 142 (Supplement 1): 6872.
https://doi.org/10.1182/blood-2023-191153
Published: 2023
Journal Articles

Incidence and Outcomes of Pneumocystis Pneumonia Following Chimeric Antigen Receptor T-Cell Therapy: A Real-World Analysis

Jiasheng Wang, Michael Daunov, Brenda W Cooper
Journal: Blood
Blood (2023) 142 (Supplement 1): 6897.
https://doi.org/10.1182/blood-2023-190785
Published: 2023
Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne
Journal: Blood
Blood (2023) 142 (Supplement 1): 483.
https://doi.org/10.1182/blood-2023-190037
Published: 2023
Journal Articles

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Jeries Kort, Sathya Sri Areti, Nikolas Naleid, Brenda W Cooper, Ehsan Malek
Journal: Blood
Blood (2023) 142 (Supplement 1): 6706.
https://doi.org/10.1182/blood-2023-190931
Published: 2023
Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 7457–7459.
https://doi.org/10.1182/blood-2022-170629
Published: 2022
Journal Articles

Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy

Jiasheng Wang, Srilatha Dasari, Michael Daunov, Kanithra Sekaran, Yeseong Kim, Brenda W. Cooper
Journal: Blood
Blood (2022) 140 (Supplement 1): 9889–9890.
https://doi.org/10.1182/blood-2022-167875
Published: 2022
Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel
Journal: Blood
Blood (2022) 140 (Supplement 1): 12973–12975.
https://doi.org/10.1182/blood-2022-165289
Published: 2022
Journal Articles

Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Jiasheng Wang, Benjamin Tomlinson, Ehsan Malek, Leland Metheny, Molly Gallogly, Marcos de Lima, Merle Kolk, Brenda W. Cooper
Journal: Blood
Blood (2022) 140 (Supplement 1): 12831–12832.
https://doi.org/10.1182/blood-2022-163589
Published: 2022
Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima
Journal: Blood
Blood (2022) 140 (Supplement 1): 1887–1889.
https://doi.org/10.1182/blood-2022-169935
Published: 2022
Journal Articles

Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients

Akiva Diamond, Sabarish Ayyappan, Shufen Cao, Nour Tashtish, Kirsten M Boughan, Brenda W. Cooper, Pingfu Fu, Paolo F. Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2536.
https://doi.org/10.1182/blood-2021-153862
Published: 2021
Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Paolo F. Caimi, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Julie K Ritchey, Tabatha Trummer, Jennifer Schiavone, Kayla Zamborsky, Linda G Eissenberg, Julia Hollaway, Dina Schneider, Kristen Bakalarz, Kirsten M Boughan, Leland Metheny, III, Seema Patel, Erin Galloway, Molly Gallogly, Winfried Krueger, Michael Kadan, Gabriela Pacheco Sanchez, Ashish Sharma, David Wald, Brenda W. Cooper, John F. DiPersio, Rafick Sekaly, Rimas J Orentas, Boro Dropulic, Marcos J.G. de Lima
Journal: Blood
Blood (2021) 138 (Supplement 1): 3833.
https://doi.org/10.1182/blood-2021-151155
Published: 2021
Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2488.
https://doi.org/10.1182/blood-2021-152225
Published: 2021
Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima
Journal: Blood
Blood (2021) 138 (Supplement 1): 2899.
https://doi.org/10.1182/blood-2021-153041
Published: 2021
Journal Articles

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Brian T. Hill, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Robert M. Dean, MD, Omer N. Koc, MD, Matt Kalaycio, MD, Kirsten M Boughan, DO, Brenda W. Cooper, MD, Allison M. Winter, MD, Wesam B. Ahmed, MD, Brad Pohlman, MD, Christopher D'Andrea, PA-C, Kelsey Holkovic, RN, Ashley Morrison, RN, Paolo Caimi, MD, Mitchell Smith, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136370
Published: 2020
Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-142197
Published: 2020